These studies suggested that CDA1/CDA1BP1 axis targeting by genetic and pharmacological approaches is a safe and effective method to attenuate pathological hallmarks and to inhibit renal fibrosis of experimental DN. The gene discussed is TSPYL2; the disease is liver dysplastic nodule.